3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Leukemia
7
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Myeloid
2
Gastrointestinal Stromal Tumors
2
Bone Marrow Diseases
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Blast Crisis
1
Interventions
Carboplatin
4
Sunitinib
3
Rituximab
3
Pemetrexed
3
ponatinib
2
pembrolizumab
2
osimertinib
2
Vincristine
2
Prednisone
2
Gemcitabine
2
Etoposide
2
Doxorubicin
2
Cyclophosphamide
2
ricolinostat
1
pralsetinib
1
pomalidomide
1
nilotinib
1
linifanib
1
ibritumomab tiuxetan
1
emvododstat
1
atezolizumab
1
Temozolomide
1
Taxes
1
Sorafenib
1
Papanicolaou Test
1
Paclitaxel
1
Melphalan
1
Irinotecan
1
Interleukin-2
1
Imatinib Mesylate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Neoplasms by Histologic Type
×
nilotinib
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts